Preformulation Consideration for Drugs in Oral CR Formulation

Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice

Volumn , Issue , 2010, Pages 47-69

  Ku, Mannching Sherry ^a  

^a PFIZER INC   (United States)

Author keywords

Drug substance stress testing identifing likely degradation products; Preformulation for drugs in oral CR formulation preparative work on drug before drug product formulation; Solubility, critical drug substance property for controlled release dosage form development

Indexed keywords

EID: 84859988826     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470640487.ch4     Document Type: Chapter

References (29)

1. Zhang Y, Johnson KC. Effect of drug particle size on content uniformity of low-dose solid dosage forms. Int. J. Pharm. 1997; 154:179-183.
2. Rohrs BR, Amidon GE, Meury RH, Secreast PJ, King HM, Skoug CJ. Particle size limits to meet USP content uniformity criteria for tablets and capsules. J. Pharm. Sci. 2006;95: 1049-1059.
3. Huang CY, Ku SM. Prediction of drug particle size and content uniformity in low-dose solid dosage forms. Int. J. Pharm. 2010;383(1-2):70-80.
4. Schussele A, Bauer-Brandl A. Note on the measurement of flowability according to the European Pharmacopoeia, Int. J. Pharm. 2003;257:301.
5. Standard Shear Test Method for Bulk Solids Using the Schulze Ring Shear Tester. ASTM D6773-02.
6. Amidon GE, Houghton ME. Powder flow testing in preformulation and formulation development. Pharm. Manuf. 1985 (July); 21-31.
7. Wells JI. Pharmaceutical Preformulation, Ellis Harwood Limited, 1988.
8. Murphy D, Rabel S. Thermal analysis and calorimetric methods for the characterization of new crystal forms. In Adeyeye MC, Brittain HG, editors. Preformulation in Solid Dosage Form Development, Informa Healthcare USA Inc., 2008.
9. Waterman KC, et al. Stabilization of pharmaceuticals to oxidative degradation. Pharm. Dev. Technol. 2002;7(1):1-32.
10. Connors KA, Amidon GL, Stella VJ. Chemical stability of pharmaceuticals: a handbook for pharmacists. Wiley, Second edition,1986.
11. Monkhouse DC, Maderich A. Whither compatibility testing? Drug Dev. Ind. Pharm. 1989;15:2115-2130.
12. Serajuddin A, Thakur A, Ghoshal R, Fakes M, Ranadive S, Morris K, Varia S. Selection of solid dosage form composition through drug-excipient compatibility testing. J. Pharm. Sci. 1999;88:696-704.
13. Byrn SR, Pfeiffer RR, Stowell JG. Solid State Chemistry of Drugs, 2nd edition, SSCI Inc., 1999, pp. 305-441.
14. Ku, MS. Use of the Biopharmaceutical Classification System in Early Drug Development. The AAPS Journal 2008;10 (1):208-212.
15. Avdeef A. High throughput measurements of solubility profiles. In Testa B, van de Waterbeemd H, Folkers G, Guy R, editors. Pharmacokinetic Optimization in Drug Research: Biological, Physiological, and Computational Strategies, Verlag Helvetica Chimica Acta, Zurich, 2001, pp. 305-326.
16. Pan L, Ho Q, Tsutsui K, Takahashi L. Comparison of chromatographic and spectroscopic methods used to rank compounds for aqueous solubility. J Pharm. Sci. 2001;90:521-529.
17. Fiese EF, Hagen TA. Preformulation. In Lachman L, Lieberman HA, Kanig JL, editors. The Theory and Practice of Industrial Pharmacy, Lea & Febiger, 1986, pp. 96-171.
18. Dressman JB, Amidon GL, Reppas C, et al. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 1998;15(1):11-22.
19. Charman WN, Porter CJH, Mithani S, et al. Physicochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J. Pharm. Sci. 1997;86(3): 269-282.
20. Galia E, Nicolaides E, Horter D, et al. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res. 1998;15(5): 698-705.
21. Jones HM, Parrott N, Ohlenbusch G, Lave T. Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling. Clin. Pharmacokinet. 2006;45:1-15.
22. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 2005;22:11-23.
23. Ku, MS. An oral formulation decision tree based on the biopharmaceutical classification system for first in human clinical trials. Bull. Tech. Gattefosse. 2006;99:89.
24. Leopold G. Experimental factors influencing the results of drug product bioavailability/bioequivalency studies in humans. In Smolen VF, Ball LA, editors. Controlled Drug Bioavailability: BioavailabilityMethodology and Regulation,Vol.2,Wiley,1984, pp. 7-9.
25. Farag SI, Munir B, Hussain A. Minireview: microenvironmental pH modulation in solid dosage forms. J. Pharm. Sci., 2007;96:948-959.
26. Martin A. Physical Pharmacy, 4th edition, Lea & Febiger, 1993, pp. 342-351.
27. Ku, MS, Berge, S., Bansal, P. Overlapping pKa Determination by Non-Linear Regression Analysis of pH-Dependent Partition Measurements. APhA 1985;15(2):85.
28. Dunn WJ, Block JH, Pearlman RS. Partition Coefficient: Determination and Estimation, Pergamon Press, Oxford, 1986.
29. Rekker RE. The Hydrophobic Fragment Constant, Elsevier, Amsterdam, 1976.